The results revealed that the LSD1 inhibitor SP-2509 sensitized neoantigen-expressing tumor cells to CAR-T cell therapy by releasing an antigen-independent killing signal through the FAS-FASL axis by inhibiting the H3K9me3 level of FAS [213]. Here, FAS is linked to neoplasm.